Protective role of nitric oxide in indomethacin-induced gastric ulceration by a mechanism independent of gastric acid secretion

Pharmacological Research, Vol. 43, No. 5, 2001doi:10.1006/phrs.2001.0801, available online at http://www.idealibrary.com on PROTECTIVE ROLE OF NITRIC OXIDE IN INDOMETHACIN-INDUCED
GASTRIC ULCERATION BY A MECHANISM INDEPENDENT OF GASTRIC
ACID SECRETION
MAHMOUD M. KHATTABa, MOHAMED Z. GADb,∗ and DALAAL ABDALLAHa aPharmacology Department, Faculty of Pharmacy, Cairo University, Egypt, bBiochemistry Department, Faculty of Pharmacy, Cairo University, Egypt Gastric ulceration was induced in rats by i.p. injection of the non-steroidal anti-inflammatorydrug (NSAID), indomethacin (IND) (30 mg kg−1). Pyloric ligation was carried out in each animalbefore injection to enable collection of the gastric juice. Three hours later, the animals were killedand their stomachs were removed. In the gastric juice, the amounts of mucin, pepsin and HCl wereassessed. Gastric mucosa were scrapped for the determination of nitric oxide (NO) (as nitrite) afterevaluation of the gastric ulcer index.
The influence of arginine (ARG) (300 mg kg−1), a NO precursor, NG-nitro-L-arginine methyl ester (L-NAME) (50 mg kg−1), a non-selective constitutive nitric oxide synthase/inducible nitricoxide synthase (cNOS/iNOS) inhibitor, and the selective iNOS inhibitor aminoguanidine (AMG)(50 mg kg−1) were studied. Each NO modulator was injected i.p. 30 min before IND administration.
Results indicated that IND elevated gastric acidity by 80% of the normal group, decreased non-significantly mucosal nitrite by 22% and exhibited a remarkably high ulcer index (χ = 17). Neithermucin nor pepsin levels were significantly altered. In comparison with the IND group, pretreatmentwith L-NAME caused a significant decrease in gastric HCl, further decrease in mucosal nitrite (50%of normal) and a two-fold increase in the ulcer index score (χ = 34), despite the decrease in HCl.
AMG did not alter gastric acidity, decreased mucosal nitrite by 38% of the normal value and failedto alter significantly the ulcer index of IND. On the other hand, pretreatment with ARG did not alterthe gastric acidity and raised mucosal nitrite by 10% above normal. Surprisingly, ARG improvedthe gastric ulcer score (χ = 1) almost similar to the normal score (χ = zero). Therefore, this studycreates a new pathway for the potential treatment of NSAID gastric ulceration through modulationof NO synthesis, regardless of the effect on gastric acidity.
KEY WORDS: nitric oxide, indomethacin, gastric ulcer, arginine, NOS inhibitors.
INTRODUCTION
induced by various agents However, the role ofNO in regulation and maintenance of the functions of The use of non-steroidal anti-inflammatory drugs gastric mucosa has not yet been fully understood.
(NSAIDs) is limited by their ulcerogenic activity as The present investigation was therefore designed to well as their ability to interfere with ulcer healing.
explore the biochemical effects of the NO precursor, These effects are mainly mediated through inhibition of L-arginine (ARG), and the nitric oxide synthase (NOS) prostaglandin synthesis Recently, many strategies inhibitors, NG-nitro-L-arginine methyl ester (L-NAME), have been adopted to minimize the NSAID-induced gastropathy. These include the development of NSAIDs (cNOS/iNOS) inhibitor, and the selective iNOS inhibitor that only inhibit the inducible isoform of cyclooxygenase aminoguanidine (AMG) on indomethacin (IND)-induced (COX-2) [] and coupling of NSAIDs with a nitric oxide gastric ulceration, gastric acid secretion as well as mucin (NO)-releasing molecule NO donors have been re- and pepsin secretions. The level of the mucosal NO was peatedly shown to protect gastric mucosa against damage examined after each treatment. The ultimate goal wasto understand the role of NO in the regulation of gastric ∗Corresponding author. Associate Professor, Biochemistry Department, acid secretion and to search for a simple protective Faculty of Pharmacy, Cairo University, Kasr El-Aini st, Cairo 11672, mechanism against NSAID-induced gastropathy.
Pharmacological Research, Vol. 43, No. 5, 2001 MATERIALS AND METHODS
20 min was measured colorimetrically at 680 nm. A blankexperiment was similarly carried out using 1 ml of N/100 HCl. In addition, a standard solution containing 0.2 ml Male Wistar albino rats weighing 150-200 g were used working tyrosine standard made up to 1 ml with N/100 in this study. The rats were treated in humane conditions and were allowed free access to water and diet ad libitumuntil the beginning of the experiment. All experimental protocols were approved by the Animal Care Committee The method adopted is based on the determination of the hexose component of the mucin. It depends on thereaction of carbohydrate in concentrated sulfuric acid with Orcinol (5-methyl resorcinol) to give a colored Rats were deprived of food, but not water, for about product that can be measured colorimetrically. In detail, 18-24 h before the experiment. For each rat, the abdomen 0.25 ml of 1 : 20 diluted juice was added to an equal was then incised and the pylorus was ligated under ether volume of 1.6% Orcinol and 2 ml of 60% sulfuric acid.
anesthesia. Indomethacin (30 mg kg−1 suspended in 1% The mixture was boiled in a water bath for 10 min and Tween 80) was given intraperitoneally immediately after then cooled on ice. The optical density was measured at pyloric ligation. Three hours later, animals were killed 425 nm. Results are expressed as mg hexose dl−1 with an ether overdose. A normal group that was treatedsimilarly but without administration of indomethacin was Determination of gastric ulcer index After collection of the gastric juice, the stomach of each animal was then rinsed with saline and inflated on cork.
The ulcer index was expressed as the sum of the length Three groups of rats were given intraperitoneally (mm) of all lesions in the fundic region [].
30 min before pyloric ligation either the NO precursor, L-arginine (300 mg kg−1), or the NOS inhibitors L-NAME Determination of mucosal nitric oxide (50 mg kg−1) or AMG (50 mg kg−1). Doses of drugs Finally, the gastric mucosa of each rat was scrubbed were in homogeny with previous reports , ].
off, weighed and its nitric oxide content was determinedas nitrite by diazotization with sulfanilic acid at acidic pH and subsequent coupling with N-1-naphthyl-ethylene After the animals were killed, their stomachs were re- diamine to give a colored product that was measured moved following ligature of the oesophocardiac junction, washed with distilled water and dried between filter paperand opened along the greater curvature. The gastric juice was drained and centrifuged at 3500 rpm and used for Data are presented as mean ± SEM for 6-10 animals.
Statistical significance between groups was evaluatedusing analysis of variance (ANOVA). In all data analysis, P values of 0.05 or less were considered significant Titratable acidity in the supernatant of the gastric juice was determined by titration with 0.01 M NaOHusing phenol red as an indicator. Units are expressed as As shown in Table IND elevated significantly gastric acidity by 80% above that of the normal group. This Peptic activity is a major factor involved in the prote- elevation was normalized by pretreatment with L-NAME.
olytic activity of gastric secretion. Measured pepsin ac- Pretreatment with AMG or ARG failed to significantly tivity represents the amount of liberated tyrosine (µmol) modify the elevated gastric acid secretion. Neither IND per 1 ml of gastric juice per minute, using 1:100 diluted nor any pretreatment had a significant effect on mucin gastric juice and 2% bovine albumin in N/100 HCl as a content or peptic activity of the gastric juice.
substrate. In detail, each sample of the gastric juice was With regard to the effects on gastric ulcer formation, first diluted 1:100 with N/100 HCl. One ml of the diluted IND treatment induced a remarkably high ulcer index juice was added to 5 ml of 2% bovine serum albumin so- (x = 17) (Fig. ). Pretreatment with L-NAME further lution. The mixture was incubated at 37 ◦C for exactly aggravated the ulcer formation as reflected by a two- 10 min in a water bath. At the end of the incubation pe- fold increase in the ulcer index score (x = 34). AMG riod, 10 ml of 0.3 M trichloroacetic acid was then added pretreatment failed to alter significantly the ulcer index and the mixture was boiled for 5 min. The solution was score as compared to the IND index. On the other hand, then centrifuged for 5 min at 3000 rpm and filtered. To ARG profoundly improved the gastric ulcer score (x = 1) 1 ml of the filtrate 2 ml of 0.5 N NaOH and 0.2 ml of to almost that of the normal score (x = 0).
Folin reagent were added. The color that developed after Concerning the effect of treatments on mucosal nitrite Pharmacological Research, Vol. 43, No. 5, 2001 HCl level, mucin content and pepsin activity in the gastric juice of normal, indomethacin, L-NAME, aminoguanidine, and L-arginine treated
rats. Results are mean ± SEM of 6-10 animals
a Significantly different from IND at P< 0.01. bSignificantly different from normal at P< 0.05. Units are mEq l−1 for HCl, mg hexose dl−1 for mucin, µmol ml−1 min−1 for pepsin.
with the NO precursor, L-arginine, and the aggravation of ulcer formation by pretreatment with the NOS inhibitor, L-NAME. These effects were, interestingly, independent of gastric acid secretion or other measured factors such as pepsin activity or mucin content. Rather, they are well correlated with mucosal nitrite level.
In support of this conclusion, several reports from dif- ferent laboratories have demonstrated the importance of endogenous NO in the protection of gastric mucosa. Two studies from Pique's laboratory [, ] have shown thatNO plays a vasodilatory role in the gastric microcircula- Ulcer index (mm) of normal, indomethacin, L-NAME, tion during acid secretion. Other studies have accredited aminoguanidine, and L-arginine treated rats. Results are mean ± SEMof 6-10 animals. (∗∗) Significantly different from indomethacin at P< the role of NO as an endogenous modulator of leukocyte adhesion In support, Calatayud et al. [haverecently shown that transdermal nitroglycerin protectedagainst indomethacin-induced gastric ulceration through maintenance of mucosal blood flow and reduction of leukocyte-endothelial cell rolling and adherence. In ad- dition, Wallace ] stated that reduction of gastric blood flow is the main predisposing factor in the induction of Reports have not restricted the role of NO to gastric protection, but also include the acceleration of ulcer healing. Konturek et al. [have shown that glyceryltrinitrate was capable of ulcer healing and suppression of NO synthesis resulted in impaired ulcer healing. It is possible that NO directly accelerates ulcer repair by Level of mucosal nitrite (µg g−1 tissue) in normal, in- promoting the growth of smooth muscles as suggested by domethacin, L-NAME, aminoguanidine, and L-arginine treated rats. Re- sults are mean ± SEM of 6-10 animals. (∗) Significantly different from Our data show a close agreement between the preven- indomethacin at P< 0.05. (++) Significantly different from normal at tion of ulcer formation produced by L-arginine against indomethacin-induced ulceration and the maintenance ofmucosal NO. This agreement was also found for the ef- (Fig. IND decreased non-significantly mucosal nitrite fect of the NOS inhibitor, L-NAME, which aggravated ul- by 22%. In contrast, all pretreatments, as anticipated, cer formation. It is noticeable that, although AMG, a se- affected mucosal nitrite content either by reduction (50% lective iNOS inhibitor, lowered significantly gastric mu- with L-NAME and 38% with AMG) or elevation (10% cosal nitrite, it failed to significantly alter indomethacin- with ARG) as compared with the values of the normal induced damage. This suggests that cNOS may be the ma- Other than the role of NO in maintenance of blood flow, NO may protect against NSAID damage by pro- DISCUSSION
motion of prostaglandin synthesis. A mutual interactionwas shown to exist between NOS and cyclooxygenase The present study refers to the importance of mucosal NO (COX) enzymes. NO donors were shown to enhance in the protection against NSAID-induced gastric ulcera- COX activity whereas NOS inhibitors blocked PGE2 tion. Evidence is clearly demonstrated by the prevention production In addition, indomethacin, a COX of IND-induced gastric ulcer formation by pretreatment inhibitor, reduced the level of cyclic GMP that was Pharmacological Research, Vol. 43, No. 5, 2001 increased by NO donors [This may explain the 22% decrease in mucosal NO by indomethacin administration 2. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of in-ducible cyclooxygenase 2 in vivo is anti-inflammatory and nonul- Results of the studies investigating the effect of NOS cerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
inhibitors on gastric acid secretion are quite controver- 3. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham M, sial. While Pique et al. [found that inhibition of NOS Cirino G. Novel nonsteroidal anti-inflammatory drug deriva- tives with markedly reduced ulcerogenic properties in the rat. Gas- L-NMMA did not affect either basal or pentagastrin- troenterology 1994; 107: 173-9.
stimulated acid secretion, Kato et al. ] showed that 4. Lopez-Belmonte J, Whittle BJ, Moncada S. The actions of nitric inhibition of NO synthesis by L-NAME stimulated oxide donors in the prevention or induction of injury to the rat the increase of acid secretion induced by pentagastrin gastric mucosa. Br J Pharmacol 1993; 108: 73-8.
by using an ex vivo stomach chamber. In accordance, 5. Andrews FJ, Malcontenti Wilson C, O'Brien PE. Protection against ischemia-reperfusion injury by nitric oxide generators. Dig Martinez-Cuesta et al. [demonstrated the role of Dis Sci 1994; 39: 366-73.
NO in the endotoxin-induced inhibition of pentagastrin- 6. Calatayud S, Sanz ML, Canet A, Bello R, Diaz de Rojas F, Es- stimulated acid secretion and that L-NAME antagonized plugues JV. Mechanisms of gastroprotection by transdermal ni- this inhibition. In contrast, Bilski et al. [observed troglycerin in the rat. Br J Pharmacol 1999; 127: 1111-8.
7. Takeuchi K, Kato S, Takehara K, Asada Y, Yasuiro T. Role that NO inhibition failed to affect basal acid secretion but of nitric oxide in mucosal blood flow response and the healing reduced acid secretion stimulated by pentagastrin or meat of HCl-induced lesions in the rat stomach. Digestion 1997; 58:
feeding. Thus, in the scope of these controversial reports, it seems that control of gastric acid secretion is not of 8. Takeuchi K, Yasuhio T, Asada Y, Sugawa Y. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats.
prime importance as a mechanism for the prevention of Digestion 1998; 59: 298-307.
gastric ulceration induced by NO donors or aggravation 9. Shay H, Sun DC, Gruenstein MD. A quantitative method for mea- of gastric ulceration by NO inhibitors. This conclusion suring spontaneous gastric secretion in the rat. Gastroenterology complies well with the data presented in this study. While 1954; 26: 906-13.
10. Grossman MI. Physiology for physician. A Monthly Publication L-NAME antagonized the indomethacin-stimulated acid of the American Physiological Society 1963; 1: 1-5.
secretion, L-arginine administration failed to modify 11. Sanyal AR, Denath OK, Bhattacharya SK, Gode KD. The effect significantly acid secretion. We assume that not only of cyproheptadine on gastric acidity. In: Peptic ulcer. Pfeiffer CJ, pharmacological factors, but also hemodynamic factors ed. Scandinavian University Books, Munksgoard, 1971: 312-8.
12. Winzler RJ. Determination of serum glycoproteins. In: Methods determine the influence of NO precursors and inhibitors of biochemical analysis. Glick DP, ed. New York: Interscience on gastric acid secretion. We postulate that the inhibitory effect of L-NAME on indomethacin-induced gastric acid 13. Valcavi U, Caponi R, Brambilla A, Palmira F, Fumagali R.
secretion is possibly related to local gastric ischemia and Gastric anti-secretory, anti-ulcer and cytoprotective properties of9-hydroxy-19,20-bis-nor-prostanoic acid in experimental animals.
that the prevention of gastric ulceration by L-arginine Arzneimittel Forschung 1982; 32: 657-63.
profoundly observed in this study is not directly related 14. Ignarro L, Buga G, Wood K, Byrns R, Chaudhuri G. Endothelium- to an effect on gastric acid secretion. On the same derived relaxing factor produced and released from artery and vein line, other NO donors, such as nitrofenac and glyceryl is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9.
trinitrate, were shown to accelerate gastric ulcer healing 15. Pique JM, Whittle BJ, Esplugues JV. The vasodilator role of endogenous nitric oxide in the rat gastric microcirculation. Eur by a mechanism independent of modification of gastric J Pharmacol 1989; 174: 293-6.
acid secretion ]. Although other studies have reported 16. Pique JM, Esplugues JV, Whittle BJ. Endogenous nitric oxide as that indomethacin also increases pepsinogen secretion, a mediator of gastric mucosal vasodilataion during acid secretion.
we did not find in this study significant changes in pepsin Gastroenterology 1992; 102: 168-74.
17. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous activity after indomethacin administration. This may be modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; related to differences in the other studies in the timing 88: 4651-5.
of measurement of pepsin activity and/or duration of 18. Calatayud S, Sanz MJ, Canet A, Bello R, Diaz de Rojas F, Es- treatment with indomethacin, as indomethacin was given plugues JV. Mechanisms of gastroprotection by transdermal ni-
troglycerin in the rat. Br J Pharmacol 1999; 127: 1111-8.
19. Wallace JL. Non-steroidal anti-inflammatory drugs and gastropa- In conclusion, results of this study show that L-arginine thy: the second hundred years. Gastroenterology 1997; 112:
induced gastric ulceration by a mechanism independent 20. Konturek SJ, Brzozowski T, Majka J, Pytko-Polonczyk J, Stachura J. Inhibition of nitric oxide synthetase delays healing of modulation of acid secretion, mucin content or pepsin of chronic gastric ulcers. Eur J Pharmacol 1993; 239: 215-7.
activity, but via maintenance of mucosal NO. Thus, this 21. Hogaboam CM, Jacobson K, Collins SM. The selective beneficial study focuses the attention for an alternative pathway effects of nitric oxide inhibition in experimental colitis. Gastroen- for treating the universal problem of NSAID-induced terology 1994; 106: A700.
22. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes.
Proc Natl Acad Sci USA 1993; 90: 7240-4.
REFERENCES
23. Failli P, Cecchi E, Tosti-Guerra C, Mugelli A, Laffi G, Zilletti L, Giotti A. Effect of some cyclooxygenase inhibitors on theincrease in guanosine 3':5'-cyclic monophosphate induced by 1. Penny AG, Andrews FJ, O'Brien PE. Effects of misoprostol on NO-donors in human whole platelets. Br J Pharmacol 1998; 123:
delayed ulcer healing induced by aspirin. Dig Dis Sci 1994; 39:
Pharmacological Research, Vol. 43, No. 5, 2001 24. Kato S, Kitamura M, Korolkiewicz RP, Takeuchi K. Role of nitric 26. Bilski J, Kontuek SJ, Cieszkowski M, Czarnobilski K, Paw- oxide in regulation of gastric acid secretion in rats: effects of NO lik WW. Endogenous nitric oxide in the regulation of gastric acid donors and NO synthase inhibitors. Br J Pharmacol 1998; 123:
secretion, gastric release and blood flow. Biomed Res 1994; 15:
25. Martinez-Cuesta MA, Barrachino MD, Pique JM, Whittle BJR, 27. Elliot SN, Mcknight W, Cirino G, Wallace JL. A nitric oxide- Esplugues JV. The role of nitric oxide and platelet-activating fac- releasing nonsteroidal anti-inflammatory drug accelerates gastric tor in the inhibition by endotoxin of pentagastrin-stimulated gas- ulcer healing in rats. Gastroenterology 1995; 109: 524-30.
tric acid secretion. Eur J Pharmacol 1992; 218: 351-4.

Source: http://level1diagnostics.com/research/P/ProtectiveRoleOfNitricOxideInIndomethacin-InducedGastricUlcerationByAMechanismIndependentOfGastricAcidSecretion.pdf

Microsoft word - lidocream-10

Rox-San Pharmacy LIDOCREAM-10 (Lidocaine Cream 10%) Active Ingredients: Lidocaine 10% Product(s): Lidocaine is a local anesthetic that has neuron membrane stabilizing effect. Topical lidocaine is mostly used in combination with other agents (NSAIDs, muscle relaxants, NMDA-receptor antagonist, and etc…). Lidocaine produces pain relief by blocking the signals at the nerve endi

(no al visado para los antipsicÓticos atÍpicos)

EL VISADO PARA LOS ANTIPSICÓTICOS ATÍPICOS ES INACEPTABLE Las alteraciones de conducta en el Alzheimer. Tratamiento farmacológico Los síntomas psicológicos y conductuales asociados a demencia (SPCD) son frecuentes entre los pacientes que padecen esta enfermedad. Existe suficiente evidencia que indica que estas alteraciones tienen una prevalencia en torno al 60-80 % y un riesgo de padecerlas

Copyright © 2018 Predicting Disease Pdf